1-6 of 6
Jianxin Lin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Journal: Blood
Blood (2023) 142 (10): 878–886.
https://doi.org/10.1182/blood.2022019386
Published: 2023
Includes: Supplemental data
Journal Articles

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Philippe Armand, Pier Luigi Luigi Zinzani, Hun Ju Lee, Nathalie Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Journal: Blood
Blood (2021) 138 (Supplement 1): 1366.
https://doi.org/10.1182/blood-2021-147881
Published: 2021
Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
https://doi.org/10.1182/blood-2020-142565
Published: 2020
Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 240.
https://doi.org/10.1182/blood-2019-127280
Published: 2019
Journal Articles

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Clinical Trials & Observations
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (14): 1144–1153.
https://doi.org/10.1182/blood.2019000324
Published: 2019
Includes: Supplemental data
Journal Articles

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Craig H. Moskowitz, MD, Robert W. Chen, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD, Theodoros P. Vassilakopoulos, MD PhD, Gregory V. Goldmacher, MD PhD MBA, Jianxin Lin, MS, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Gilles Salles, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4085.
https://doi.org/10.1182/blood.V130.Suppl_1.4085.4085
Published: 2017